Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Intensity Therapeutics Treats First Patient

30 May 2017 12:45

RNS Number : 5219G
SalvaRx Group plc
30 May 2017
 

 

SalvaRx Group PLC

("SalvaRx" or "the Company")

Intensity Therapeutics Treats First Patient

 

SalvaRx is pleased to notify that Intensity Therapeutics Inc. ("Intensity"), in which the Company has an 8.5 per cent interest, has announced that the first patient has been dosed with INT230-6 as part of a Phase 1/2 international clinical study. Dr Ian B. Walters, Chief Executive of SalvaRx, has helped design the study and oversaw the medical aspects of INT230-6 as Chief Medical Officer of Intensity. Initiation of the study followed acceptance of an investigational new drug (IND) submission made by Intensity to the U.S. Food and Drug Administration's Division of Oncology Products 1 (DOP1) and receipt from Health Canada of a No Objection Letter. The clinical trial, IT-01 (NCT#03058289), entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers aims to enroll approximately 60 patients with several different types of advanced solid tumors.

 

"Bringing our novel product into human testing is a major milestone for Intensity Therapeutics," commented Lewis H. Bender, President and CEO of Intensity, "Over the past few years Intensity has demonstrated impressive tumor shrinkage in several murine models of cancers. Our product, INT230-6, eradicated large tumors, activated a systemic immune response and improved survival. Some animals having a complete response show no evidence of regrowth for the remainder of their lives. In fact, many acquired the capability to spontaneously clear additional challenges of the same cancer (suggesting a protection effect similar to that of a vaccine). We are therefore excited to have initiated human testing of INT230-6. Our staff, investigators, and clinical centers are enthusiastic about bringing patients our potentially life-saving product."

Intensity's Phase 1/2 study will first assess the safety of INT230-6. Initial tumor types treated will be those at the skin surface (e.g. breast, melanoma, head-and-neck and lymphoma). Subsequent patients receiving INT230-6 will include those with deep tumors (e.g. liver, pancreatic, colon, lung cancers, and others). Investigators will utilize image guidance to inject the tumors. A cohort is planned to study INT230-6 in combination with anti-PD1 agents. The study's primary goal is to demonstrate the safety of INT230-6. Secondary analyses will examine the efficacy of INT230-6 treatment via multiple parameters. The trial includes several adaptive components that will allow for adjustments in patient groups, dosing schedule and dose volumes administered.

 

"Our studies with INT230-6 have shown the ability to stimulate a strong T-cell response as a monotherapy, and there is considerably enhanced activity using INT230-6 in combination with checkpoint inhibitors such as anti-PD-1 antibodies, while maintaining a favorable safety profile," said Intensity's Chief Medical Officer Ian B. Walters, MD, "We are optimistic that our novel trial design can quickly detect evidence of direct tumor killing and immune system activation. Physicians desperately need improved treatments for patients with advanced cancers that are not responding to approved immunotherapies. Intensity is grateful to the volunteers participating in our study and looks forward to collecting data on INT230-6 in different cancer types."

 

Enquiries

 

SalvaRx Group PLC

Ian Walters (Chief Executive)

Tel: +1 203 441 5451

Northland Capital Partners Limited

Nominated Adviser and Broker

Tel: +44 (0) 20 3861 6625 

 

Matthew Johnson / Edward Hutton (Corporate Finance)

John Howes (Corporate Broking)

 

Peterhouse Corporate Finance Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

 

 

Notes

 

About INT230-6

INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. INT230-6 was identified from Intensity's DfuseRxSM platform and is being evaluated in a clinical trial; IT-01. In preclinical studies INT230-6 administration eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. Treatment with INT230-6 in in vivo models of severe cancer resulted in substantial improvement in overall survival compared to standard therapies. Further, INT230-6 provided complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers.

 

About Study IT-01

IT-01 is entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers. The trial aims to enroll approximately 60 patients with different types advanced solid tumor malignancies in a multicycle dosing regimen. The study will be conducted in multiple countries and includes a cohort combining INT230-6 with an anti-PD-1 antibody. Currently the study is recruiting in the U.S. at two hospitals associated with the University of Southern California (USC) and in Canada at the University Health Network (UHN) in Toronto. The principal investigator at USC is Dr. Anthony El-Khoueiry; the principal investigator at UHN is Dr. Lillian Siu.

 

The study's primary objective is to assess the safety and tolerability of multiple intratumoral doses of INT230-6. Secondary assessments are to understand preliminary efficacy of INT230-6 by measuring the injected and bystander tumor responses. The study will characterize the systemic pharmacokinetic profile of multiple doses of INT230-6's drug substances after single and then multiple intratumoral injections. Exploratory analysis will characterize patient outcome, as well as evaluate various tumor and anti-tumor immune response biomarkers that may correlate with response. Data will be used to assess the progression free and overall survival in subjects receiving INT230-6. Further information including estimated completion date can be found at www.clinicaltrials.gov (NCT#03058289).

 

About SalvaRx

SalvaRx Limited was founded in 2014 to develop therapies within the rapidly growing immuno-oncology market, which uses treatments designed to boost the body's natural defences to fight the cancer. Immuno-oncology therapy is a fast growing and new therapeutic area, a market expected to grow to $80 billion worldwide by 2020 (Global & USA Cancer Immunotherapy Market Analysis 2020). SalvaRx Limited is majority owned by SalvaRx Group PLC.

 

In addition to Intensity Therapeutics, SalvaRx manages a portfolio of cancer immunotherapy companies which includes iOx Therapeutics, a University of Oxford spin-out company developing products that stimulate Natural Killer T-Cells, RIFT Therapeutics a San Diego company focused on developing novel antibody targets to the tumor micro-environment, and Nekonal Oncology, a BVI company developing novel immune-oncology antibodies.

 

SalvaRx's strategy is to invest in and acquire a portfolio of companies involved in novel cancer immunotherapies and develop them up to clinical proof of concept. SalvaRx provides portfolio companies with operational support in addition to capital, either by managing its portfolio companies directly or augmenting an existing team. SalvaRx's management team have a proven track record of discovering and commercialising drugs in the area of cancer immunotherapy with Bristol-Myers Squibb and Johnson & Johnson. The team is supported by an extended network of senior academic and industry executives to promote commercial and scientific outcomes, including licensing and partnering discussions.

 

For more information please visit: www.salvarx.io

Ends

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCAMMRTMBBJMLR
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.